AVITA Medical Reveals 36% Hospital Stay Reduction, Cohealyx Interim Data at ABA
AVITA Medical showcased new Cohealyx interim analysis and investigator-led case data at the 2026 ABA Annual Meeting, with 19 presentations and three company-sponsored events highlighting its wound care portfolio. Early findings include a 36% reduction in hospital stay with RECELL and time-to-grafting endpoints in the Cohealyx-I multi-center study.
1. ABA 2026 Presentation
AVITA Medical participated in the 2026 American Burn Association Annual Meeting, hosting three company-sponsored events and delivering 19 presentations across its RECELL, Cohealyx and PermeaDerm wound care portfolio, introducing a holistic approach to burn and acute wound management.
2. Cohealyx Interim Analysis
Interim analysis from the Cohealyx-I multi-center study evaluated time to skin grafting as the primary endpoint, and investigator-led case series demonstrated the collagen-based dermal matrix’s efficacy in supporting graft readiness across complex wound scenarios.
3. RECELL and PermeaDerm Outcomes
RECELL data showcased a 36% reduction in hospital length of stay for deep partial-thickness burns, while PermeaDerm findings underscored optimized resource utilization and improved donor site healing, reinforcing the suite’s potential to accelerate patient recovery.